Cargando…

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

AIMS: The aim of this study was to evaluate the haemodynamic effects of serelaxin (30 µg/kg/day 20-h infusion and 4-h post-infusion period) in patients with acute heart failure (AHF). METHODS AND RESULTS: This double-blind, multicentre study randomized 71 AHF patients with pulmonary capillary wedge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponikowski, Piotr, Mitrovic, Veselin, Ruda, Mikhail, Fernandez, Alberto, Voors, Adriaan A., Vishnevsky, Alexander, Cotter, Gad, Milo, Olga, Laessing, Ute, Zhang, Yiming, Dahlke, Marion, Zymlinski, Robert, Metra, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	FASTTrack Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924183/ https://www.ncbi.nlm.nih.gov/pubmed/24255129 http://dx.doi.org/10.1093/eurheartj/eht459

Ejemplares similares

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
por: Steg, Ph. Gabriel, et al.
Publicado: (2011)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy
por: Gold, Michael R., et al.
Publicado: (2011)

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
por: Lefèvre, Thierry, et al.
Publicado: (2011)

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
por: Matsa, Elena, et al.
Publicado: (2011)

Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study
por: Tanaka, Hidekazu, et al.
Publicado: (2010)

Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation
por: Hjortnaes, Jesper, et al.
Publicado: (2010)

Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter
por: Templin, Christian, et al.
Publicado: (2013)

Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial
por: Worthley, Stephen G., et al.
Publicado: (2013)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve
por: Bairey Merz, C. Noel, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)

Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study(†)
por: Budera, Petr, et al.
Publicado: (2012)

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
por: Goto, Shinya, et al.
Publicado: (2010)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
por: Pitt, Bertram, et al.
Publicado: (2013)

Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)
por: Mont, Lluís, et al.
Publicado: (2014)

Vasodilators in the treatment of acute heart failure: what we know, what we don’t
por: Metra, Marco, et al.
Publicado: (2008)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011)

Variants in the 3′ untranslated region of the KCNQ1-encoded K(v)7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner
por: Amin, Ahmad S., et al.
Publicado: (2012)

A novel clinical method for quantification of regional left ventricular pressure–strain loop area: a non-invasive index of myocardial work
por: Russell, Kristoffer, et al.
Publicado: (2012)

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
por: Lauten, Alexander, et al.
Publicado: (2011)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

The German Aortic Valve Registry (GARY): in-hospital outcome
por: Hamm, Christian W., et al.
Publicado: (2014)

Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity
por: Fiechter, Michael, et al.
Publicado: (2013)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012)

Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium(†)
por: Riegger, Julia, et al.
Publicado: (2016)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial
por: Haude, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_52vvgh3qkusfsk13pp3nkuqb98